Duane A. Mitchell

13.1k total citations · 4 hit papers
181 papers, 9.0k citations indexed

About

Duane A. Mitchell is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Duane A. Mitchell has authored 181 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Immunology, 105 papers in Oncology and 54 papers in Molecular Biology. Recurrent topics in Duane A. Mitchell's work include Immunotherapy and Immune Responses (95 papers), CAR-T cell therapy research (57 papers) and Cancer Immunotherapy and Biomarkers (50 papers). Duane A. Mitchell is often cited by papers focused on Immunotherapy and Immune Responses (95 papers), CAR-T cell therapy research (57 papers) and Cancer Immunotherapy and Biomarkers (50 papers). Duane A. Mitchell collaborates with scholars based in United States, China and Germany. Duane A. Mitchell's co-authors include John H. Sampson, Darell D. Bigner, Gary E. Archer, Elias Sayour, James E. Herndon, Smita K. Nair, Allan H. Friedman, Roger E. McLendon, David A. Reardon and Maryam Rahman and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Duane A. Mitchell

172 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

2010 613 citations John H. Sampson, Amy B. Heimberger et al. Journal of Clinical Oncology profile →
A large language model for electronic health records

2022 434 citations Duane A. Mitchell et al. profile →
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

2015 410 citations Duane A. Mitchell, Kristen A. Batich et al. profile →
Cancer mRNA vaccines: clinical advances and future opportunities

2024 94 citations Elias Sayour, David Boczkowski et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Duane A. Mitchell United States	48	4.7k	4.0k	2.8k	2.8k	1.1k	181	9.0k
John S. Yu United States	49	3.1k 0.7×	4.2k 1.0×	2.7k 1.0×	3.3k 1.2×	692 0.6×	171	8.7k
Robert M. Prins United States	38	3.1k 0.7×	3.0k 0.7×	3.0k 1.1×	3.5k 1.3×	363 0.3×	140	8.7k
Ravindra Majeti United States	55	7.4k 1.6×	3.9k 1.0×	1.5k 0.5×	8.0k 2.9×	762 0.7×	161	16.4k
Catherine J. Wu United States	57	6.4k 1.4×	6.3k 1.6×	1.9k 0.7×	5.4k 2.0×	678 0.6×	270	14.2k
Keith L. Knutson United States	55	6.7k 1.4×	6.4k 1.6×	2.2k 0.8×	4.7k 1.7×	862 0.8×	187	14.3k
Dario Campana United States	85	7.7k 1.7×	7.6k 1.9×	2.5k 0.9×	5.2k 1.9×	1.0k 0.9×	287	22.5k
Dominique Bonnet United Kingdom	52	4.2k 0.9×	6.0k 1.5×	3.2k 1.1×	7.2k 2.6×	743 0.7×	180	16.4k
Pierre‐Yves Dietrich Switzerland	47	3.3k 0.7×	2.7k 0.7×	1.6k 0.6×	2.5k 0.9×	236 0.2×	174	7.4k
Marc Schmitz Germany	46	3.2k 0.7×	2.8k 0.7×	851 0.3×	2.0k 0.7×	478 0.4×	173	6.4k
William H. Yong United States	49	1.7k 0.4×	1.9k 0.5×	3.0k 1.1×	2.9k 1.1×	633 0.6×	179	8.7k

Countries citing papers authored by Duane A. Mitchell

Since Specialization

Citations

This map shows the geographic impact of Duane A. Mitchell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Duane A. Mitchell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Duane A. Mitchell more than expected).

Fields of papers citing papers by Duane A. Mitchell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Duane A. Mitchell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Duane A. Mitchell. The network helps show where Duane A. Mitchell may publish in the future.

Co-authorship network of co-authors of Duane A. Mitchell

This figure shows the co-authorship network connecting the top 25 collaborators of Duane A. Mitchell. A scholar is included among the top collaborators of Duane A. Mitchell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Duane A. Mitchell. Duane A. Mitchell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Love, Christopher, et al.. (2025). OS05.5.A RADIAL GLIAL CELLS AS SOURCE ANTIGEN FOR ADOPTIVE CELLULAR THERAPY IN GLIOBLASTOMA. Neuro-Oncology. 27(Supplement_3). iii18–iii18.

Yang, Changlin, et al.. (2024). Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma. Genome Medicine. 16(1). 102–102. 4 indexed citations

Yang, Changlin, Christina A. Von Roemeling, Lan Hoang-Minh, et al.. (2024). mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors. Genome Medicine. 16(1). 17–17. 28 indexed citations

Doonan, Bently P., Shawna C. Willey, Ji‐Hyun Lee, et al.. (2024). Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy.. Journal of Clinical Oncology. 42(16_suppl). TPS9609–TPS9609. 2 indexed citations

Roemeling, Christina A. Von, Changlin Yang, Bently P. Doonan, et al.. (2024). Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade. Nature Communications. 15(1). 5871–5871. 5 indexed citations

Luo, Defang, et al.. (2023). Glioma-derived CCL2 and CCL7 mediate migration of immune suppressive CCR2+/CX3CR1+ M-MDSCs into the tumor microenvironment in a redundant manner. Frontiers in Immunology. 13. 993444–993444. 32 indexed citations

Ogando‐Rivas, Elizabeth, John A. Ligon, Linchun Jin, et al.. (2023). Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions. Acta Biomaterialia. 172. 466–479. 9 indexed citations

Dean, Joseph, Changlin Yang, Connor Francis, et al.. (2023). Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis. Journal for ImmunoTherapy of Cancer. 11(2). e004805–e004805. 3 indexed citations

Yang, Changlin, Andria Doty, Shu Wang, et al.. (2022). Slow-Cycling Cells in Glioblastoma: A Specific Population in the Cellular Mosaic of Cancer Stem Cells. Cancers. 14(5). 1126–1126. 7 indexed citations

10.

Wang, Yifan, Yaqing Qie, Hengfeng Yuan, et al.. (2020). Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nature Communications. 11(1). 1508–1508. 187 indexed citations

11.

Dyson, Kyle, Connor Francis, Changlin Yang, et al.. (2020). Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. Clinical Cancer Research. 26(21). 5689–5700. 31 indexed citations

12.

Long, Yu, Haipeng Tao, Aida Karachi, et al.. (2019). Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Research. 80(3). 499–509. 93 indexed citations

13.

Grippin, Adam, et al.. (2018). Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. Clinical Cancer Research. 24(16). 3955–3966. 27 indexed citations

14.

Batich, Kristen A., Elizabeth A. Reap, Gary E. Archer, et al.. (2017). Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clinical Cancer Research. 23(8). 1898–1909. 242 indexed citations

15.

Pham, Christina, Catherine Flores, Changlin Yang, et al.. (2015). Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clinical Cancer Research. 22(3). 582–595. 87 indexed citations

16.

Nair, Smita K., Gabriel De Leon, David Boczkowski, et al.. (2014). Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells. Clinical Cancer Research. 20(10). 2684–2694. 74 indexed citations

17.

Sampson, John H., Amy B. Heimberger, Gary E. Archer, et al.. (2010). Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. Journal of Clinical Oncology. 28(31). 4722–4729. 613 indexed citations breakdown →

18.

Sampson, John H., Gary E. Archer, Duane A. Mitchell, et al.. (2009). An epidermal growth factor receptor variant III–targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Molecular Cancer Therapeutics. 8(10). 2773–2779. 221 indexed citations

19.

Fecci, Peter E., Hidenobu Ochiai, Duane A. Mitchell, et al.. (2007). Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function. Clinical Cancer Research. 13(7). 2158–2167. 265 indexed citations

20.

Mitchell, Duane A., et al.. (1995). Identification of a ras -Activated Enhancer in the Mouse Osteopontin Promoter and Its Interaction with a Putative ETS-Related Transcription Factor Whose Activity Correlates with the Metastatic Potential of the Cell. Molecular and Cellular Biology. 15(1). 476–487. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact